title: Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.
abstract: Among the atypical antipsychotics, clozapine and olanzapine are known to cause significant weight gain. Along with quetiapine, they may impair glucose metabolism and increase the risk for type 2 diabetes. They are also associated with a rise in triglyceride levels and an increased risk for coronary artery disease. Clinicians should take these risks seriously in prescribing these antipsychotics and employ intelligent safeguards if and when they use them.
authors.affiliation: Department of Biological Psychiatry, Innsbruck University Clinics, Innsbruck, Austria.
authors.forename: Ursula
authors.initials: U
authors.lastname: eder-Ischia
authors.forename: Christoph
authors.initials: C
authors.lastname: Ebenbichler
authors.forename: W Wolfgang
authors.initials: WW
authors.lastname: Fleischhacker
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D020738:Leptin / Q000096:biosynthesis; D018377:Neurotransmitter Agents / Q000037:antagonists & inhibitors; D000077152:Olanzapine; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D020738:Leptin; D018377:Neurotransmitter Agents; D001569:Benzodiazepines; D000077152:Olanzapine